AGEN Aug 2024 2.000 put
| Previous Close | 1.3700 |
| Open | 1.3700 |
| Bid | 1.4500 |
| Ask | 1.8500 |
| Strike | 2.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 1.3700 - 1.3700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11 |
- Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
LEXINGTON, Mass., May 23, 2024--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.
- Business Wire
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
LEXINGTON, Mass., May 16, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as the
Insider MonkeyAgenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript May 7, 2024 Agenus Inc. beats earnings expectations. Reported EPS is $-3.04104, expectations were $-3.1. AGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to […]
